Switch theme
Sign up to access all valuation multiples
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
1986
3
LTM Revenue $1.6M
LTM EBITDA -$82.6M
$156M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Imugene has a last 12-month revenue of $1.6M and a last 12-month EBITDA of -$82.6M.
In the most recent fiscal year, Imugene achieved revenue of n/a and an EBITDA of -$90.1M.
Imugene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Imugene valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$32.3M | -$90.1M | XXX | XXX | XXX |
| EBITDA Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Profit | -$23.9M | -$24.8M | XXX | XXX | XXX |
| Net Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 17, 2025, Imugene's stock price is AUD 0 (or $0).
Imugene has current market cap of AUD 268M (or $169M), and EV of AUD 247M (or $156M).
See Imugene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $156M | $169M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 17, 2025, Imugene has market cap of $169M and EV of $156M.
Imugene's trades at 98.9x LTM EV/Revenue multiple, and -1.9x LTM EBITDA.
Analysts estimate Imugene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Imugene and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $156M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpImugene's NTM/LTM revenue growth is -100%
Imugene's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $30.7M for the same period.
Over next 12 months, Imugene's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Imugene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Imugene and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 179% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $30.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| European Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Imugene acquired XXX companies to date.
Last acquisition by Imugene was XXXXXXXX, XXXXX XXXXX XXXXXX . Imugene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Imugene founded? | Imugene was founded in 1986. |
| Where is Imugene headquartered? | Imugene is headquartered in Australia. |
| How many employees does Imugene have? | As of today, Imugene has 3 employees. |
| Who is the CEO of Imugene? | Imugene's CEO is Ms. Leslie Chong. |
| Is Imugene publicy listed? | Yes, Imugene is a public company listed on ASX. |
| What is the stock symbol of Imugene? | Imugene trades under IMU ticker. |
| When did Imugene go public? | Imugene went public in 1993. |
| Who are competitors of Imugene? | Similar companies to Imugene include e.g. CSL, Prescient Therapeutics, GSK India, AstraZeneca India. |
| What is the current market cap of Imugene? | Imugene's current market cap is $169M |
| What is the current revenue of Imugene? | Imugene's last 12-month revenue is $1.6M. |
| What is the current EBITDA of Imugene? | Imugene's last 12-month EBITDA is -$82.6M. |
| What is the current EV/Revenue multiple of Imugene? | Current revenue multiple of Imugene is 98.9x. |
| What is the current EV/EBITDA multiple of Imugene? | Current EBITDA multiple of Imugene is -1.9x. |
| Is Imugene profitable? | Yes, Imugene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
